Lianjia Ma
About Lianjia Ma
Lianjia Ma is the CMC Analytical Team Lead/Associate Scientific Director at Bristol Myers Squibb in New Jersey, United States, with extensive experience in analytical chemistry and pharmaceutical development.
Current Position
Lianjia Ma serves as the CMC Analytical Team Lead/Associate Scientific Director at Bristol Myers Squibb, based in New Jersey, United States. In this role, Ma leads teams to support the development of Antibody Drug Conjugates (ADC) and identifies critical quality attributes (CQA) for their development and characterization. This position involves overseeing both internal and external analytical activities to ensure timely completion of release and stability testing, and that all necessary documentation is issued promptly.
Previous Roles at Bristol Myers Squibb
Lianjia Ma has held various roles at Bristol Myers Squibb. From 2021 to present, Ma was CMC Analytical Team Lead/Senior Principal Scientist in New Jersey. Prior to that, served as CMC Analytical Lead/Principal Scientist from 2019 to 2021 for two years in Summit. Earlier positions include Analytical Project Team Leader from 2010 to 2018, and Senior Research Investigator from 2005 to 2018 in New Brunswick, NJ.
Experience at Celgene
Lianjia Ma worked at Celgene as a Principal Scientist from 2018 to 2019 in Summit. The expertise gained during this period contributed to Ma's extensive knowledge in modern separation sciences and analytical chemistry.
Educational Background
Lianjia Ma has a Ph.D. in Analytical Chemistry from the University of Minnesota, completed between 2000 and 2005. Ma also holds an MS in Analytical Chemistry from Iowa State University, from 1997 to 2000, and a BS in Physical Chemistry from the University of Science and Technology of China, where studied from 1992 to 1997.
Analytical Chemistry Expertise
Lianjia Ma has extensive expertise in modern analytical techniques including HPLC, LC-MS, GC, GC-MS, Ion Chromatography, and Capillary Electrophoresis (CE). Ma has developed and validated quantitative LC-MS/UV and GC-MS methods for genotoxic impurity analysis, and has extensive experience with Mass Spectrometry (Mass Spec), Karl Fischer titration (KF), FTIR, HIAC, NMR, and SEM.
Regulatory and Quality Assurance Roles
Lianjia Ma collaborates with multiple external contract service providers for drug substance and drug product manufacture, release, and stability studies. In this capacity, Ma ensures that all results meet specifications via deviation, OOS, and OOT investigations. Furthermore, Ma provides necessary data and analytical method reports for regulatory submissions and assists in preparing and reviewing regulatory documentation, addressing health agency questions with global filings.